drugset / Trial / NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
Timeline
- Start
- 2021-03-19
- Primary completion
- 2025-08-25
- Completion
- 2025-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RALZAPASTOTUG | Monoclonal antibody | — | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | 360 mg | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | 480 mg | Intravenous |